Full Press Release Details
Therapeutics Reschedules 2022 Annual Stockholders Meeting
Sets New Record Date
Boston, MA U.S.A. (December
1, 2022) - Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical
company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized
cancer care, today announced that the Company's adjourned 2022 Annual Stockholders Meeting ("2022 ASM") set for December
2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting ("2023 ASM") will be held, as a virtual
meeting, on January 19, 2023.
As previously announced,
the Company's 2022 ASM on November 4, 2022 was adjourned to December 2, 2022, without any business being conducted to allow additional
time to achieve quorum and for stockholders to vote on the proposals set forth in the Company's definitive proxy statement filed
with the U.S. Securities and Exchange Commission ("SEC") on September 19, 2022.
The annual meeting was
rescheduled to January 19, 2023 in light of the new proposals to be considered at the annual meeting. Stockholders of record as of December
6, 2022, will be entitled to notice of, and to vote at, the 2023 ASM. A proxy statement for the 2023 ASM, to be held on January 19, 2023,
will be filed with the SEC and notice will be provided to the stockholders of record on or about December 9, 2022. The Company, however,
reserves the right to change the record date prior to the 2023 ASM.
About Allarity Therapeutics
Allarity Therapeutics,
Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic
technology, the DRP platform. The Company has a mature portfolio of four drug candidates: stenoparib, a PARP inhibitor
in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor being prepared for a Phase 1b combination
study together with stenoparib; IXEMPRA (Ixabepilone), a microtubule inhibitor approved in the U.S. for the treatment
of second-line metastatic breast cancer and in Phase 2 development in Europe for the same indication; and 2X-111, a liposomal formulation
of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions
for a restructured out-license to Smerud Medical Research International AS. LiPlaCis , a liposomal formulation of cisplatin
and its accompanying DRP , is being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research
International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility
in Hoersholm, Denmark. For more information, please visit the Company's website at www.Allarity.com
About the Drug Response
Predictor - DRP Companion Diagnostic
drug-specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood
of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high
DRP score, the therapeutic response rate can be significantly increased. The DRP method builds on the
comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical
tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP
platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in
cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective
Phase 2 trials of Stenoparib and IXEMPRA . The DRP platform, which can be used in all cancer types and
is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.
Facebook: https://www.facebook.com/AllarityTx/
Twitter: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements provide Allarity's current expectations or forecasts of future events. The words "anticipates," "believe,"
"continue," "could," "estimate," "expect," "intends," "may,"
"might," "plan," "possible," "potential," "predicts," "project,"
"should," "would" and similar expressions may identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, all statements
under the heading "Anticipated Milestones in 2022," statements relating to the Company's NDA submission for dovitinib
and its PMA submission for the drug-specific DRP companion diagnostic for dovitinib, any statements related to ongoing
clinical trials for stenoparib for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA
for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Company's DRP
companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking
statements in this press release are based on management's current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study
do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive
reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation
and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of
our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of
any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously
conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that
the current COVID-19 pandemic will impact the Company's current and future clinical trials and the timing of the Company's
preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk
Factors" in our Form 10-K for the year ended December 31, 2021 filed today with the Securities and Exchange Commission,
available at the Securities and Exchange Commission's website at www.sec.gov, and as well as discussions of potential risks,
uncertainties and other important factors in the Company's subsequent filings with the Securities and Exchange Commission.
All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information
unless required by law.
of Investor Relations